Broker lifts target price for Genus as turnaround gathers pace

Shore Capital has raised its fair value target for Genus PLC to 2,900p from 2,750p, maintaining a 'buy' rating, citing stronger cash conversion, accelerated debt reduction, and improving margins, particularly within its bovine (ABS) division. The broker lifted 2025 adjusted profit before tax forecasts to £72 million, driven by a robust rebound in the porcine (PIC) business, aided by a shift to stable royalty-based agreements, and a successful cost-cutting turnaround in ABS. Despite a demanding valuation at 32 times next year's earnings, Shore believes Genus's enhanced financial position, growing royalty income, and proprietary product pipeline justify further upside and position the company for potential acquisitions.

Analysis

Shore Capital has raised its fair value estimate for Genus PLC to 2,900p, maintaining a 'buy' rating based on a strengthening operational and financial outlook. The upgrade is underpinned by better-than-expected cash conversion, forecast to reach 170% of earnings, and accelerated debt reduction, with net debt projected to fall to £223 million this year from £249 million. The company's two key divisions are showing significant improvement. The porcine (PIC) division's adjusted operating profit is expected to grow by nearly 13% in 2025, driven by a strategic shift toward more stable, royalty-based agreements. Concurrently, the bovine (ABS) division is undergoing a successful turnaround, with a productivity program anticipated to add over £21 million to operating profit on a run-rate basis and lift margins toward a target of 12% by FY29. While the stock trades at a demanding valuation of 32 times next year's earnings after a 53% rally, the broker justifies this with the growing royalty income stream and the long-term potential of its proprietary PRRS-resistant pig program. A potential headwind remains in the form of Chinese restrictions on bovine semen imports.

Key Decisions for Investors

• Investors should consider the positive operational momentum and improved financial health, including strong cash flow and debt reduction, which supports the broker's view of further upside despite the stock's significant recent appreciation.
• The demanding valuation at 32 times forward earnings requires careful assessment; potential investors must weigh the premium against the strong projected earnings growth, rising margins in the ABS division, and long-term innovation pipeline.
• Key risks to monitor include any changes to China's import policies for bovine semen, which could impact the ABS division's recovery, and the execution risk associated with the company's renewed capacity for potential M&A activity.